First US cell-therapy trial for kidney transplant patients launched at University of Wisconsin Health

By ASN Staff

“The UW Program for Advanced Cell Therapy (PACT) will use the personalized cell therapy treatment to study its effects on a viral infection faced by around 30-40% of kidney and/or pancreas transplant recipients.

Nearly one in three children is infected with CMV by age 5, according to the Centers for Disease Control and Prevention. It can cause fever, sore throat, fatigue, and swollen glands. For people with stable immune systems, the virus is usually kept in check and doesn't cause symptoms. For transplant patients, their immune system is suppressed and an infection could be fatal.

The Federal Drug Administration-approved trial will begin enrolling 20 adult kidney-transplant recipients, according to Dr. Arjang Djamali, professor of medicine and surgery at the UW School of Medicine and Public Health, and UW Health nephrology division chief.”

For more information, please see the news report.

Category:
Subcategory:
Author:
ASN Staff
Article Image:
Body:

“The UW Program for Advanced Cell Therapy (PACT) will use the personalized cell therapy treatment to study its effects on a viral infection faced by around 30-40% of kidney and/or pancreas transplant recipients.

Nearly one in three children is infected with CMV by age 5, according to the Centers for Disease Control and Prevention. It can cause fever, sore throat, fatigue, and swollen glands. For people with stable immune systems, the virus is usually kept in check and doesn't cause symptoms. For transplant patients, their immune system is suppressed and an infection could be fatal.

The Federal Drug Administration-approved trial will begin enrolling 20 adult kidney-transplant recipients, according to Dr. Arjang Djamali, professor of medicine and surgery at the UW School of Medicine and Public Health, and UW Health nephrology division chief.”

For more information, please see the news report.

Date:
Tuesday, August 6, 2019